Online citations, reference lists, and bibliographies.
← Back to Search

Surgical Assessment Of Malignant Pleural Mesothelioma: Have We Reached A Critical Stage?

A. Nakas, E. Black, J. Entwisle, S. Muller, D. Waller
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
OBJECTIVE The International Mesothelioma Interest Group (IMIG) classification is the most widely used staging system but is based on post-resectional parameters. We aimed to test the association between clinical and pathological staging and to identify possible discrepancies. METHODS We identified 164 consecutive patients (144 males and 20 females, with mean age 58 years) who underwent radical surgery (114 extrapleural pneumonectomy; 50 radical pleurectomy/decortication) for malignant pleural mesothelioma (MPM). The patients were clinically staged with CT + or - MRI (CT, computed tomography; MRI, magnetic resonance imaging). RESULTS Clinical T (cT) stage proved to be the same as pathological T (pT) stage in 44%; understaged in 46% and overstaged in 10%. Clinical N (cN) stage proved to be the same as pathological N (pN) stage in 56%; understaged in 31% and overstaged in 13%. Disease-free interval (DFI) was associated with cT stage (median DFI 29 months, SE 13, 95% CI 3-54 months for cT1; median 5, SE 3, 95% CI 3-6 months for cT4, p=0.02) but not clinical N stage (median DFI 12 months, SE 1, 95% CI 9-15 months for cN0; median DFI 11 months, SE 0.3, 95% CI 10-12 months for cN2, p=0.5) and was associated with both pT (median DFI 31 months, SE 17, 95% CI 0-64 months for pT1; median DFI 8 months, SE1, 95% CI 6-11 months for pT4, p=0.03) and pN stage (median DFI 14 months, SE 3, 95% CI 9-20 months for pN0; median DFI 10 months, SE 1, 95% CI 8-13 months for pN2, p=0.02). Overall survival was associated with cT stage (median survival 25 months, SE 3, 95% CI 20-30 months for cT1; median survival 11 months, SE 3, 95% CI 10-11 months for cT4, p=0.01) but not cN stage (median survival 15 months, SE 2, 95% CI 11-19 months for cN0; median survival 15 months, SE 2, 95% CI 12-19 months for cN2, p=0.49) and pN stage (median survival 22 months, SE 3, 95% CI 19-27 months for pN0; median survival 14 months, SE 1, 95% CI 12-17 months for pN2, p=0.01) but not pT stage (median survival 27 months, SE 4, 95% CI 19-35 months for pT1; median survival 12 months, SE 2, 95% CI 9-15 months for pT4, p=0.06). Pathological IMIG stage was associated with DFI and overall survival; however, preoperative IMIG stage was less useful. CONCLUSIONS There are deficiencies in the current staging system for MPM and discrepancies between clinical and pathological systems. Future improvements are needed in clinical descriptors of nodal status and pathological descriptors of T stage. Subsequent IMIG stage grouping also needs revision.
This paper references
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
TNM Classification of Malignant Tumours
L. Sobin (1987)
Diseases of the pleura.
R. Light (1995)
AJCC cancer staging handbook
F. L. Greene (2002)
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia
A. Hasani (2009)
Staging and response to therapy of malignant pleural mesothelioma.
R. Heelan (2004)
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma.
T. Mineo (2008)
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
D. Sugarbaker (1993)
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma.
J. Pilling (2004)
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)

This paper is referenced by
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
H. Doi (2019)
Malignant pleural mesothelioma signs and symptoms
Elisa Roca (2015)
Malignant pleural mesothelioma.
A. Tsao (2009)
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
S. Kao (2013)
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma
R. Gill (2018)
Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma.
A. Nakas (2012)
Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma
M. Hashimoto (2019)
Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma.
C. Yang (2016)
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
R. Gill (2012)
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
V. Rusch (2012)
Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Malignancies—Experience from Indian Centers
M. D. Patel (2018)
Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
R. Meyerhoff (2015)
Multi-modality Imaging of Pleural and Peritoneal Disease
J. Cunningham (2018)
Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?
N. van Zandwijk (2012)
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
D. Sugarbaker (2013)
Staging malignant pleural mesothelioma: additional investigation may not improve accuracy.
D. West (2011)
Role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of malignant pleural mesothelioma.
Ori Wald (2016)
The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma.
A. Nakas (2012)
Semantic Scholar Logo Some data provided by SemanticScholar